Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kimberly Cooper

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Archives of Women'S Mental Health|January 1, 2022
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trialsRobyn R Jones, Marlene P Freeman, Susan G Kornstein, et al.
Journal of Psychopharmacology (Oxford, England)|November 27, 2014
A comparison of impulsivity, depressive symptoms, lifetime stress and sensation seeking in healthy controls versus participants with cocaine or methamphetamine use disordersJames J Mahoney, Daisy G Y Thompson-Lake, Kimberly Cooper, et al.
Journal of Affective Disorders|December 2, 2020
Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral AntidepressantStacie Hudgens, Lysbeth Floden, Michael Blackowicz, et al.
Clinical Drug Investigation|December 16, 2014
A pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathySherwyn Schwartz, Mila S Etropolski, Douglas Y Shapiro, et al.
JAMA Psychiatry|December 29, 2017
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical TrialElla J Daly, Jaskaran B Singh, Maggie Fedgchin, et al.
The Plant Genome|May 1, 2023
Transcript profiling of hairy vetch (Vicia villosa Roth) identified interesting genes for seed dormancyShahjahan Ali, Lisa Kissing Kucek, Heathcliffe Riday, et al.
The American Journal of Psychiatry|May 22, 2019
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled StudyVanina Popova, Ella J Daly, Madhukar Trivedi, et al.
The American Journal of Psychiatry|April 9, 2016
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant DepressionJaskaran B Singh, Maggie Fedgchin, Ella J Daly, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Archives of Women'S Mental Health|January 1, 2022
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trialsRobyn R Jones, Marlene P Freeman, Susan G Kornstein, et al.
Journal of Psychopharmacology (Oxford, England)|November 27, 2014
A comparison of impulsivity, depressive symptoms, lifetime stress and sensation seeking in healthy controls versus participants with cocaine or methamphetamine use disordersJames J Mahoney, Daisy G Y Thompson-Lake, Kimberly Cooper, et al.
Journal of Affective Disorders|December 2, 2020
Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral AntidepressantStacie Hudgens, Lysbeth Floden, Michael Blackowicz, et al.
Clinical Drug Investigation|December 16, 2014
A pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathySherwyn Schwartz, Mila S Etropolski, Douglas Y Shapiro, et al.
JAMA Psychiatry|December 29, 2017
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical TrialElla J Daly, Jaskaran B Singh, Maggie Fedgchin, et al.
The Plant Genome|May 1, 2023
Transcript profiling of hairy vetch (Vicia villosa Roth) identified interesting genes for seed dormancyShahjahan Ali, Lisa Kissing Kucek, Heathcliffe Riday, et al.
The American Journal of Psychiatry|May 22, 2019
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled StudyVanina Popova, Ella J Daly, Madhukar Trivedi, et al.
The American Journal of Psychiatry|April 9, 2016
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant DepressionJaskaran B Singh, Maggie Fedgchin, Ella J Daly, et al.
Pageof 2